Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1701-1709

  Jakesz, Raimund ^a   Hausmaninger, H ^a   Haider, K ^a   Kubista, E ^a   Samonigg, H ^a   Gnant, M ^a   Manfreda, D ^a   Tschurtschenthaler, G ^a   Kolb, R ^a   Stierer, M ^a   Fridrik, M ^a   Mlineritsch, B ^a   Steindorfer, P ^a   Mittlbock M ^a   Steger, G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033064336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1701     Document Type: Article

References (33)

1. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 94:405-410, 1976
2. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1:257-261, 1983
3. Ribeiro G, Swindell R: The Christie Hospital adjuvant tamoxifen trial: Status at 10 years. Br J Cancer 57:601-603, 1988
4. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
5. Jakesz R, Dittrich C, Hanusch ZH, et al: Simultaneous and sequential determinations of steroid hormone receptor in human breast cancer. Ann Surg 3:305-310, 1985
6. Bloom HJG, Richardson WW: Histologic grading and prognosis breast cancer. Br J Cancer 11:359-377, 1957
7. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
8. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. Am Stat Assoc 53:457-481, 1987
9. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1963
10. Cox DR: Regression model and life-tables. J R Stat Soc (B) 34:187-220, 1972
11. Jakesz R, Samonigg H, Gnant M, et al: Very low-dose adjuvant chemotherapy in steroid receptor-negative stage I breast cancer patients. Eur J Cancer 34:66-70, 1998
12. Pritchard KI, Paterson AHG, Fine S, et al: Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group-Breast Cancer Site Group. J Clin Oncol 15:2302-2311, 1997
13. Fisher B, Dignan J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
14. Slevin ML, Stubbs L, Plant HJ, et al: Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458-1460, 1990
15. Gelber RD, Cole BF, Goldhirsch A, et al: Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival. Lancet 347: 1066-1071, 1996
16. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy in 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71, 84, 1992
17. Mouridsen HT, Rose C, Overgaard M, et al: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer: Results from the Danish adjuvant trials DBCG 77C and DBCG 82 C. Acta Oncol 27:699-705, 1988
18. Hubay CA, Gordon NH, Pearson OH, et al: Eight-year follow-up of adjuvant therapy for stage II breast cancer. World J Surg 9:738-749, 1985
19. Fisher B, Redmond C, Brown A, et al: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: Five-year results from the NSABP trial. J Clin Oncol 3:144-154, 1985
20. Mauriac L, Durand M, Chauvergne J, et al: Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre. Breast Cancer Res Treat 11:179-186, 1988
21. Goldhirsch A, Gelber RD: Adjuvant chemoendocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV, in Senn HJ, Goldhirsch A, Belger RD, et al (eds): Recent Results in Cancer Research: Adjuvant Therapy of Primary Breast Cancer. Berlin, Germany, Springer Verlag, 1989, pp 153-162
22. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 5:717-724, 1944
23. Senanyake F: Adjuvant hormonal chemotherapy in early breast cancer: Early results from a controlled trial. Lancet 1:1148-1149, 1984
24. Boccardo F, Rubagotti A, Amoroso P, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients: An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) Trial. Eur J Cancer 28:673-680, 1992
25. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for post-menopausal node-positive estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study. J Clin Oncol 12:2078-2085, 1944
26. Gérard JP, Héry M, Gedouin D, et al: Postmenopausal patients with node-positive resectable breast cancer: Tamoxifen vs. FEC 50 (6 cycles) vs. FEC 50 (6 cycles) plus tamoxifen versus control preliminary results of a 4-arm randomized trial. Drugs 45:60-67, 1993 (suppl 2)
27. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385-1394, 1997
28. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
29. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol 16:1358-1362, 1998
30. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1988
31. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage I, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
32. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1998
33. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998